Martin Engell-Rossen og Omar S. Qandeel tiltræder Pharma Equity Group's bestyrelse
Half-year results have been released
We are the future of repositioning
Our mission is to develop new effective medicines for the local treatment of serious, acute and chronic inflammatory diseases that have significant consequences for patients and society and for which there is currently no optimal treatment.
Our drug development strategy
Local drug administration is very beneficial for patients as it allows for precision targeting. By delivering drugs directly to the specific area of concern, it minimizes systemic exposure to other areas of the body, reducing the risk of side effects and adverse reactions. This approach also means less exposure to metabolic processes in the liver, ensuring that the medication remains more potent and effective where it should. Lower systemic exposure and reduced metabolism translate to lower overall dose requirements, which can be a game-changer for patient safety as the amount of medication they need is reduced. In essence, local administration maximizes therapeutic benefits while minimizing potential risks. This is the foundation of Reponex Pharmaceuticals’ drug development strategy.
Our clinical pipeline
The full Pharma Equity Group drug candidate pipeline holds a total of 6 drug candidates, which are divided into the 4 treatment areas Bacterial Peritonitis, Skin Ulcer (infected Chronic and Chronic skin ulcers), Crohn’s disease and Pouchitis and finally Colorectal cancer and Colon Adenomas. Please press below link to get the clinical phase overview of each of the candidates.